Key statistics
On Friday, Beigene Ltd (6160:HKG.HS) closed at 113.80, 50.83% above the 52 week low of 75.45 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 116.80 |
---|---|
High | 117.70 |
Low | 112.90 |
Bid | 113.70 |
Offer | 113.80 |
Previous close | 116.90 |
Average volume | 1.89m |
---|---|
Shares outstanding | 1.38bn |
Free float | 1.31bn |
P/E (TTM) | -- |
Market cap | 168.93bn HKD |
EPS (TTM) | -4.93 HKD |
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Press releases
- BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
- BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
- BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
- BeiGene to Present at the Jefferies London Healthcare Conference
- BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
- BeiGene Mourns Death of Beloved Board Member Donald Glazer
- BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
- BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024
- BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
- Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
More ▼